Mazdutide

Mazdutide is the world’s first dual GLP-1 receptor and glucagon receptor agonist, approved in China (June 2025) for chronic weight management. This once-weekly injectable leverages synergistic metabolic effects by:

GLP-1 receptor activation - glucose-dependent insulin secretion, appetite suppression.
Glucagon receptor activation - increased energy expenditure.

Weight Loss: 11.0–15.4% reduction at 48 weeks; 82% achieved ≥5% weight loss; 50% achieved ≥10%
Glycemic Control: HbA1c reductions of 1.41–2.23%; 71.2–74.2% achieved HbA1c <7%
Liver Fat: 80.2% reduction at 6 mg dose vs 5.3% placebo
Cardiovascular: 7.57–9.21 mmHg systolic BP reduction; 43.29% decrease in triglycerides
Dual Endpoint Success: 59.9% of T2D patients achieved HbA1c <7% and ≥5% weight loss
Visceral Fat Loss: Preferential reduction in visceral adiposity; improved body composition
Energy Balance: Combines anabolic and catabolic pathways for metabolic optimization
Insulin Sensitivity: Reduced fasting insulin, HOMA-IR, and serum uric acid
Tolerability: No GI adverse events causing withdrawal reported

GLORY-1 Trial, New England Journal of Medicine, 2025 – Once-weekly Mazdutide in Chinese Adults with Obesity or Overweight (Phase 3)
Phase 2 RCT, Nature Communications, 2023 – Mazdutide in Chinese overweight adults
Diabetes Care, 2024 – Efficacy and Safety in Chinese T2D patients (Phase 2)
Phase 1b Trial, EClinicalMedicine, 2022 – Safety and efficacy of Mazdutide 9mg and 10mg
Meta-Analysis, Frontiers in Endocrinology, 2024 – Efficacy and safety of Mazdutide for weight loss

$116.00

Per Unit

In stock